Scarica l'app Stockscreener
1.68
1.20%
0.02
Dopo l'orario di chiusura:
1.68
Precedente Chiudi:
$1.66
Aprire:
$1.675
Volume 24 ore:
9.94M
Relative Volume:
3.81
Capitalizzazione di mercato:
$191.34M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7742
EPS:
-2.17
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
-8.20%
1M Prestazione:
-24.32%
6M Prestazione:
-53.20%
1 anno Prestazione:
-45.10%
Intervallo 1D:
$1.6404
$1.80
Intervallo di 1 settimana:
$1.59
$2.065
Portata 52W:
$1.59
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.68 | 191.34M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World
Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com
Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com
Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Raises Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
FATE stock touches 52-week low at $1.96 amid market challenges - Investing.com
FATE stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - The Manila Times
Fate Therapeutics Presents New Phase 1 Clinical Data of - GlobeNewswire
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for - EIN News
Fate Therapeutics' Off-the-Shelf CAR T Shows Breakthrough Results in Lupus TreatmentPhase 1 Data - StockTitan
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics makes Bob Valamehr president and CEO - MSN
Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) PT at $6.75 - MarketBeat
Bob Valamehr to succeed CEO Scott Wolchko at Fate - BioCentury
Fate Therapeutics appoints new CEO as Wolchko retires By Investing.com - Investing.com Australia
Fate Therapeutics Announces Leadership Transition for 2025 - TipRanks
Fate Therapeutics Taps Bob Valamehr to Be CEO - MarketWatch
Fate Therapeutics Announces Leadership Transition - The Manila Times
Fate Therapeutics appoints new CEO as Wolchko retires - Investing.com
Fate Therapeutics, Inc. Announces President Changes - Marketscreener.com
Vestal Point Capital LP Sells 315,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Large Drop in Short Interest - MarketBeat
Fate Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook By Investing.com - Investing.com Canada
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN
Bank of America Upgrades Fate Therapeutics (NASDAQ:FATE) to Neutral - Defense World
Needham & Company LLC Reaffirms "Hold" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Thera rockets on early data for FT819 - The Pharma Letter
Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com
BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - The Manila Times
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewswire
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire
Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):